Hypoglycemia, an adverse drug event (ADE) related to insulin and sulfonylurea (SU) use, has been identified as one of the top 3 preventable ADEs by the U.S. Department of Health and Human Services. Yet the prevalence and high burden of disease in patients with Type 2 diabetes (T2D), particularly the elderly, are often underappreciated in clinical settings. Supporting the early identification and management of those at greatest risk is critical.
The Endocrine Society has embarked on a multi-year quality improvement project, the Hypoglycemia Prevention Initiative, to design and test clinical interventions in primary care settings that will aim to decrease the number of patients at high-risk and the frequency and severity of their episodes.
Clinical Practice Guidelines
The Endocrine Society has developed the following evidence-based clinical practice guidelines to help clinicians identify patients at risk for hypoglycemic events and to improve the care of their patients with diabetes:
According to the National Institute of Diabetes and Digestive and Kidney Diseases: "Hypoglycemia, also called low blood glucose or low blood sugar, occurs when the level of glucose in your blood drops below normal. Symptoms of hypoglycemia tend to come on quickly and can vary from person to person...Sometimes people don’t feel any symptoms."